Aujourd'hui Bulles Univers Watchlists Portefeuilles ETF Corrélation Playbook Articles Recherche Alertes Actualités Bots À propos

Bulletin quotidien

Un email par jour · alertes + rotations de bulles · gratuit en bêta.

À propos Articles Alertes Recherche Soutenir ♡Mentions légales Conditions Confidentialité API Suivre sur X

Actions US · Clôture quotidienne · Mis à jour chaque nuit à 22h30 Paris

Not investment advice. QuantAbundancia is educational research only. Nothing on this site is a recommendation to buy, sell, or hold any security. Past performance does not guarantee future results. Full disclosures.

We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.

Actualités

Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

4,364 signal articles · 55 in last 24h · 19,203 total before filter · latest 1h ago

55last 24h

1681last 7d

313🟢 bullish (7d)

171🔴 bearish (7d)

136publishers

ticker: IOVASentiment:

Zacks9d agobearish

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

MarketBeat9d agoneutral

Iovance Biotherapeutics Q1 Earnings Call Highlights

Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu

Zacks10d agoneutral

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks10d agoneutral

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks12d agobearish

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks17d agobearish

Pacira (PCRX) Q1 Earnings Miss Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks17d agoneutral

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IOVA

Zacks18d agoneutral

Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

✓ showing all (incl. clickbait)

IOVA